Drugs / BCD-245
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05782959 | Nov 2021 → Jun 2023 | neuroblastoma | Biocad | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05782959 ↗ |
| Modality | Monoclonal antibody | “BCD-245 (anti-GD-2 monoclonal antibody)” NCT05782959 ↗ |
| Route | Intravenous | “administered as prolonged intravenous infusions” NCT05782959 ↗ |